metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone
	IMvigor-211 (PDL1>5%), 2018 Lancet 2018;391:748-757 Eur Urol 2021 Apr 23;S0302-2838(21)00230-X. NCT02302807	RCT	mUC - L2 - PDL1 positive	atezolizumab	chemotherapy	patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen patients had received no more than two previous lines of therapy and had progressed during or following one or more platinum-containing regimens for metastatic urothelial carcinoma (or neoadjuvant or adjuvant therapy with progression)	116 / 118	some concern	inconclusive	inconclusive 13 % decrease in deaths (OS) (PE)
	IMvigor-211 (PDL1>1%), 2018 Lancet 2018;391:748-757 Eur Urol 2021 Apr 23;S0302-2838(21)00230-X. NCT02302807	RCT	mUC - L2 - PDL1 positive	atezolizumab	chemotherapy	patients with locally advanced or metastatic urothelial bladder cancer (UBC) who have progressed during or following a platinum-containing regimen patients had received no more than two previous lines of therapy and had progressed during or following one or more platinum-containing regimens for metastatic urothelial carcinoma (or neoadjuvant or adjuvant therapy with progression	316 / 309	some concern	suggested	inconclusive 13 % decrease in deaths (OS) (PE)